



Clinical trial results:

A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to increase ongoing pregnancy rate following fresh single blastocyst transfer resulting from IVF

Summary

EudraCT number	2018-002910-11
Trial protocol	HU DK ES BE PL
Global end of trial date	19 November 2020

Results information

Result version number	v1 (current)
This version publication date	21 July 2022
First version publication date	21 July 2022

Trial information

Trial identification

Sponsor protocol code	18-OBE001-010
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	ObsEva SA
Sponsor organisation address	12, Chemin des Aulx, Geneva, Switzerland, 1228
Public contact	Clinical Trial Director, ObsEva SA, 41 0225523847, clinicaltrials@obseva.ch
Scientific contact	Clinical Trial Director, ObsEva SA, 41 0225523847, clinicaltrials@obseva.ch

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 October 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	19 November 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to confirm the efficacy of a single oral 900 mg dose of nolasiban versus placebo to increase the ongoing clinical pregnancy rate at 10 weeks post-embryo transfer (ET) day.

Protection of trial subjects:

This study was to be performed in accordance with the protocol, with the ethical principles that have their origin in the Declaration of Helsinki, with the International Council for Harmonization (ICH) Harmonized Tripartite Guideline for Good Clinical Practice (GCP), with the European Union Clinical Trial Directive, and with all applicable local laws and regulations.

Before initiation of the study at a given site, written approval of the protocol, the Informed Consent Form (ICF), and any information presented to potential subjects had to be obtained from the appropriate Independent Ethics Committee (IEC).

Background therapy:

Subjects in this study were undergoing controlled ovarian hyperstimulation (COH) in preparation for IVF/ICSI according to the clinical center's practice, following a gonadotropin releasing hormone (GnRH) antagonist protocol with or without pre-treatment with an oral contraceptive pill or E2.

Final follicular maturation was to be performed with one administration of human chorionic gonadotropin (hCG) and luteal support was to be provided using vaginal micronized natural progesterone at 600 mg daily starting from the morning after oocyte pick-up (OPU) until at least the Week 6 visit (for subjects with positive pregnancy test at the Week 2 visit).

Evidence for comparator: -

Actual start date of recruitment	29 November 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 245
Country: Number of subjects enrolled	Spain: 30
Country: Number of subjects enrolled	Belgium: 16
Country: Number of subjects enrolled	Czechia: 172
Country: Number of subjects enrolled	Denmark: 78
Country: Number of subjects enrolled	Estonia: 44
Country: Number of subjects enrolled	Germany: 45
Country: Number of subjects enrolled	Hungary: 164
Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	Russian Federation: 9

Worldwide total number of subjects	810
EEA total number of subjects	794

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	810
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

First patient screened: 29Nov2018

Last patient completed: 30Sep2019

Last neonatal follow-up data: 26May2020

Last infant follow-up data: 24Oct2020

Study conducted at 47 study sites in 10 countries [Belgium (3 sites), Canada (3), Czech Republic (10), Denmark (4), Estonia (3), Germany (6), Hungary (3), Poland (6), Russia (3), and Spain (6)].

Pre-assignment

Screening details:

A total of 1264 potential subjects were screened, of whom 810 subjects were randomised. Three subjects who were all randomized to placebo were not treated, thus 807 subjects were included in the full analysis set (FAS). One subject was randomised to placebo but received nolasiban.

Period 1

Period 1 title	Treatment period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

Blinding implementation details:

As soon as the last subject completed Week 10 and the database was locked, the treatment groups were unblinded to the Sponsor; subjects and investigators remained blinded until the end of the 6-month infant follow-up.

Arms

Are arms mutually exclusive?	Yes
Arm title	Nolasiban 900 mg

Arm description:

A single oral dose of 900 mg nolasiban was to be administered to the subject at the investigational site about 4 hours prior to the embryo transfer (ET).

Arm type	Experimental
Investigational medicinal product name	nolasiban
Investigational medicinal product code	OBE001
Other name	
Pharmaceutical forms	Dispersible tablet
Routes of administration	Oral use

Dosage and administration details:

On the day of ET, subjects received a single oral dose of 900 mg nolasiban dispersed in water, approximately 4 hours prior to the transfer procedure,

Arm title	Placebo
------------------	---------

Arm description:

A single oral dose of placebo was to be administered to the subject at the investigational site about 4 hours prior to the embryo transfer (ET).

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Dispersible tablet
Routes of administration	Oral use

Dosage and administration details:

On the day of ET, subjects received a single oral dose of placebo dispersed in water, approximately 4

hours prior to the transfer procedure.

Number of subjects in period 1^[1]	Nolasiban 900 mg	Placebo
Started	398	409
Completed	161	160
Not completed	237	249
Not pregnant	205	212
Adverse event, non-fatal	31	34
No embryo transfer	-	1
Other	-	1
Subject's request	1	1

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Three subjects who were all randomised to placebo were not treated (2 due to a lack of good quality embryos, and 1 due to mistaken treatment with atosiban), thus 807 subjects were included in the FAS and SAS.

Period 2

Period 2 title	Follow-up period 1
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Blinding implementation details:

As soon as the last subject completed Week 10 and all data were locked, the treatment groups were unblinded to the Sponsor.

Subjects and investigators remained blinded until the end of the 6-month infant follow-up period 2.

Arms

Are arms mutually exclusive?	Yes
Arm title	Nolasiban 900 mg treated

Arm description:

All Women Follow-up (AWFU) Set: All subjects, treated with nolasiban, who took part in the pregnancy outcome follow-up. This was the analysis set for the analysis of pregnancy outcome data.

Arm type	Experimental
Investigational medicinal product name	nolasiban
Investigational medicinal product code	OBE001
Other name	
Pharmaceutical forms	Dispersible tablet
Routes of administration	Oral use

Dosage and administration details:

On the day of ET, subjects received a single oral dose of 900 mg nolasiban dispersed in water, approximately 4 hours prior to the transfer procedure,

Arm title	Placebo treated
------------------	-----------------

Arm description:

All Women Follow-up (AWFU) Set: All subjects, treated with placebo, who took part in the pregnancy outcome follow-up. This was the analysis set for the analysis of pregnancy outcome data.

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Dispersible tablet
Routes of administration	Oral use

Dosage and administration details:

On the day of ET, subjects received a single oral dose of placebo dispersed in water, approximately 4 hours prior to the transfer procedure.

Number of subjects in period 2	Nolasiban 900 mg treated	Placebo treated
Started	161	160
Completed	155	158
Not completed	6	2
pregnancy loss	6	2

Baseline characteristics

Reporting groups

Reporting group title	Nolasiban 900 mg
Reporting group description: A single oral dose of 900 mg nolasiban was to be administered to the subject at the investigational site about 4 hours prior to the embryo transfer (ET).	
Reporting group title	Placebo
Reporting group description: A single oral dose of placebo was to be administered to the subject at the investigational site about 4 hours prior to the embryo transfer (ET).	

Reporting group values	Nolasiban 900 mg	Placebo	Total
Number of subjects	398	409	807
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	398	409	807
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
median	32.0	32.0	
inter-quartile range (Q1-Q3)	29.0 to 34.0	29.0 to 34.0	-
Gender categorical Units: Subjects			
Female	398	409	807
Male	0	0	0

Subject analysis sets

Subject analysis set title	All infant set - nolasiban
Subject analysis set type	Safety analysis
Subject analysis set description: The All Infants (AI) Set consists of all infants born alive (whose mothers were treated with nolasiban) assessed at birth and/or at least 28 days post-delivery and/or who had adverse events recorded.	
Subject analysis set title	All infant set - placebo
Subject analysis set type	Safety analysis
Subject analysis set description: The All Infants (AI) Set consists of all infants born alive (whose mothers were treated with placebo) assessed at birth and/or at least 28 days post-delivery and/or who had adverse events recorded.	

Reporting group values	All infant set - nolasiban	All infant set - placebo	
Number of subjects	158	161	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	158	161	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous Units: years median inter-quartile range (Q1-Q3)			
Gender categorical Units: Subjects			
Female	78	67	
Male	80	94	

End points

End points reporting groups

Reporting group title	Nolasiban 900 mg
Reporting group description: A single oral dose of 900 mg nolasiban was to be administered to the subject at the investigational site about 4 hours prior to the embryo transfer (ET).	
Reporting group title	Placebo
Reporting group description: A single oral dose of placebo was to be administered to the subject at the investigational site about 4 hours prior to the embryo transfer (ET).	
Reporting group title	Nolasiban 900 mg treated
Reporting group description: All Women Follow-up (AWFU) Set: All subjects, treated with nolasiban, who took part in the pregnancy outcome follow-up. This was the analysis set for the analysis of pregnancy outcome data.	
Reporting group title	Placebo treated
Reporting group description: All Women Follow-up (AWFU) Set: All subjects, treated with placebo, who took part in the pregnancy outcome follow-up. This was the analysis set for the analysis of pregnancy outcome data.	
Subject analysis set title	All infant set - nolasiban
Subject analysis set type	Safety analysis
Subject analysis set description: The All Infants (AI) Set consists of all infants born alive (whose mothers were treated with nolasiban) assessed at birth and/or at least 28 days post-delivery and/or who had adverse events recorded.	
Subject analysis set title	All infant set - placebo
Subject analysis set type	Safety analysis
Subject analysis set description: The All Infants (AI) Set consists of all infants born alive (whose mothers were treated with placebo) assessed at birth and/or at least 28 days post-delivery and/or who had adverse events recorded.	

Primary: Number of women pregnant at week 10 week post-ET

End point title	Number of women pregnant at week 10 week post-ET
End point description:	
End point type	Primary
End point timeframe: 10 weeks after embryo transfer (ET)	

End point values	Nolasiban 900 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	398	409		
Units: number of pregnant women				
pregnant at week 10	161	160		
not pregnant at week 10	237	249		

Statistical analyses

Statistical analysis title	OPR 10 weeks post-ET
Comparison groups	Nolasiban 900 mg v Placebo
Number of subjects included in analysis	807
Analysis specification	Pre-specified
Analysis type	other ^[1]
P-value	= 0.745 ^[2]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.4

Notes:

[1] - Odds ratio and 95% CI estimated using a stratified logistic regression model with fixed effect for treatment group, age and weight categories as covariates and site as a stratification factor.

[2] - p-value calculated based on Wald chi-square statistic.

Primary: Percentage of women pregnant at week 10 post-ET

End point title	Percentage of women pregnant at week 10 post-ET
End point description:	
Intra-uterine pregnancy with fetal heartbeat at 10 weeks post-ET day.	
End point type	Primary
End point timeframe:	
Pregnant 10 weeks after embryo transfer (ET)	

End point values	Nolasiban 900 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	398	409		
Units: percent				
number (not applicable)	40.5	39.1		

Statistical analyses

Statistical analysis title	Percentage OPR 10 weeks post-ET
Statistical analysis description:	
Ongoing Pregnancy Rate (OPR) 10 weeks post-ET using the main model (FAS)	
Comparison groups	Placebo v Nolasiban 900 mg
Number of subjects included in analysis	807
Analysis specification	Pre-specified
Analysis type	other ^[3]
P-value	= 0.745 ^[4]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.05

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.4

Notes:

[3] - Odds ratio and 95% CI estimated using a stratified logistic regression model with fixed effect for treatment group, age and weight categories as covariates and site as a stratification factor.

[4] - p-value calculated based on Wald chi-square statistic.

Secondary: Number of live births after 24 weeks of gestation

End point title	Number of live births after 24 weeks of gestation
-----------------	---

End point description:

All subjects who took part in the pregnancy outcome follow-up, analyzed according to treatment received (used for the analysis of pregnancy outcome data for the subjects).

End point type	Secondary
----------------	-----------

End point timeframe:

After 24 weeks of gestation.

End point values	Nolasiban 900 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	398	409		
Units: number of live births				
Live birth - yes	155	158		
Live birth - no	243	251		

Statistical analyses

Statistical analysis title	Number of live births
Comparison groups	Nolasiban 900 mg v Placebo
Number of subjects included in analysis	807
Analysis specification	Pre-specified
Analysis type	other ^[5]
P-value	= 0.98 ^[6]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	1.34

Notes:

[5] - In this logistic regression model, subjects who were lost to follow-up were assigned as having a positive response for confirmed pregnancy at Week 10 or later.

Odds ratio and 95% CI estimated using a stratified logistic regression model with fixed effect for treatment group, age and weight categories as covariates and site as a stratification factor.

Secondary: Percentage of live births after 24 weeks of gestation

End point title	Percentage of live births after 24 weeks of gestation
-----------------	---

End point description:

All subjects who took part in the pregnancy outcome follow-up, analyzed according to treatment received (used for the analysis of pregnancy outcome data for the subjects).

End point type	Secondary
----------------	-----------

End point timeframe:

After 24 weeks of gestation.

End point values	Nolasiban 900 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	398	409		
Units: percent				
number (not applicable)	38.9	38.6		

Statistical analyses

Statistical analysis title	Live birth rate
Comparison groups	Nolasiban 900 mg v Placebo
Number of subjects included in analysis	807
Analysis specification	Pre-specified
Analysis type	other ^[7]
P-value	= 0.98 ^[8]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	1.34

Notes:

[7] - In this logistic regression model, subjects who were lost to follow-up were assigned as having a positive response for confirmed pregnancy at Week 10 or later.

Odds ratio and 95% CI estimated using a stratified logistic regression model with fixed effect for treatment group, age and weight categories as covariates and site as a stratification factor.

[8] - p-value calculated based on Wald chi-square statistic.

Secondary: Pregnancy loss rate between Week 10 and Week 24 gestation

End point title	Pregnancy loss rate between Week 10 and Week 24 gestation
-----------------	---

End point description:

Pregnancy loss rate (PLR) reported after Week 10 with lost to follow-up assigned as positive response for confirmed pregnancy at Week 2 or later (FAS).

EoP = end of pregnancy

End point type	Secondary
End point timeframe:	
Pregnancy losses reported in this table are those occurring post-Week 10 database lock.	

End point values	Nolasiban 900 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	398	409		
Units: number				
PLR between Week 10 and EoP - yes	6	2		
PLR between Week 10 and EoP - no	155	158		
PLR between Week 2 and EoP - yes	49	49		
PLR between Week 2 and EoP - no	155	158		

Statistical analyses

No statistical analyses for this end point

Secondary: Neonatal outcomes - AI Set

End point title	Neonatal outcomes - AI Set
End point description:	
Analysis of neonatal health data - condition at birth:	
In the All Infants (AI) set, 54.5% were male and 45.5% were female (placebo [P]: 58.4% and 41.6%; nolasiban [N]: 50.6% and 49.4%, respectively).	
Median weight at birth was similar in both groups (P: 3214.0 g; N: 3230.0 g). The minimum weight was 900 g in the placebo group and 1080 g in the nolasiban group. Median height was the same in both groups (51.0 cm) with mean height similar in both groups (P: 50.87 cm; N: 51.20 cm). Median head circumference was also the same in both groups (34.0 cm) with similar mean values (P: 33.81 cm; N: 33.88 cm).	
The median Apgar scores at 1 min and 5 min were identical in both groups (P: 9.0; N: 10.0).	
Congenital malformations or birth defects were reported in 6 infants in each treatment group (approx. 3.8%). Neonatal illness was reported with similar frequency in both groups (P: 6.8%; N 7.6%), as was abnormal examination of infant by a paediatrician (P: 5.0%; N: 5.7%).	
End point type	Secondary
End point timeframe:	
All Infants (AI) Set: all infants assessed at birth and/or at least 28 days post-delivery and/or who had AEs recorded.	

End point values	All infant set - nolasiban	All infant set - placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	158	161		
Units: Number of infants				
Sex - male	80	94		
Sex - female	78	67		
Congenital anomaly (at delivery)	6	6		
Neonatal illness (at delivery)	12	11		

Breastfeeding (at least 28 days after delivery)	121	127		
Admission to intensive care at least 28d post del	4	6		
Neonatal morbidities at least 28d post del	20	26		
- jaundice	13	11		
- difficulty in feeding	6	11		
- respiratory distress syndrome	4	3		
- anaemia	2	2		
- asphyxia	1	2		
- retinopathy of prematurity	1	1		
- sepsis	0	1		
- intraventricular haemorrhage	1	0		
- bronchopulmonary dysplasia	0	1		
- cerebellar haemorrhage (uni-/bilateral)	1	0		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Ages and Stages Questionnaires (ASQ-3) Abnormal Scores at Month 6

End point title	Ages and Stages Questionnaires (ASQ-3) Abnormal Scores at Month 6
-----------------	---

End point description:

Subjects were invited to complete the Ages and Stages Questionnaire-3 (ASQ-3) at 6 months after birth, corrected for gestational age at birth (i.e., at 6 months after the expected term date).

Abnormal scores were defined in the ASQ-3 User Guide as domain scores below the following cut-offs: 29.65 points for communication, 25.14 points for fine motor, 22.25 points for gross motor, 25.34 points for personal-social, and 27.72 points for problem-solving.

Only questionnaires completed within 150 days to 211 days after expected term date are included for the 6-month assessment.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

To evaluate infant development outcome at 6 months after birth (adjusted for gestational age).

End point values	All infant set - nolasiban	All infant set - placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	145	140		
Units: number of infants below the cut-off				
Communication	6	3		
Fine motor	15	11		
Gross motor	43	35		
Personal-social	28	19		
Problem solving	9	1		
Overall (one or more area below cut-off)	61	50		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

TEAEs occurring in subjects from the day of study drug administration until 28 days after delivery.
Only SAEs were collected for the fetuses / neonates (from birth up to 28 days).

Adverse event reporting additional description:

Mother: All AEs from informed consent until Week 10. From Week 10 until birth, only AEs which could affect foetal outcome or AEs that the investigator suspected were related to IMP.

Foetus: only AEs resulting in SAEs (until birth).

Neonate (from birth up to 28 days): only AEs resulting in SAEs (until 28 days).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	Safety analysis set - nolasiban
-----------------------	---------------------------------

Reporting group description:

Nosaliban 900 mg up to Week 10 Safety Analysis Set (SAS). A single oral dose of 900 mg nolasiban was administered to the subject at the investigational site about 4 hours prior to the embryo transfer (ET). The Safety Analysis Set consists of all randomised subjects who received study medication (analysed according to treatment received). Note that 1 subject was randomised to placebo but was treated with nolasiban.

Reporting group title	Safety analysis set - placebo
-----------------------	-------------------------------

Reporting group description:

Placebo up to Week 10 Safety Analysis Set (SAS). A single oral dose of matching placebo was administered to the subject at the investigational site about 4 hours prior to the embryo transfer (ET). The Safety Analysis Set consists of all randomised subjects who received study medication (analysed according to treatment received). Note that 1 subject was randomised to placebo but was treated with nolasiban.

Reporting group title	All women follow-up set - nolasiban
-----------------------	-------------------------------------

Reporting group description:

The All Women Follow-up (AWFU) Set consists of all subjects who have confirmed ongoing pregnancy at week 10. This is the analysis set for the analysis of Pregnancy Outcome data for the mothers (analysed according to treatment received).

Reporting group title	All women follow-up set - placebo
-----------------------	-----------------------------------

Reporting group description:

The All Women Follow-up (AWFU) Set consists of all subjects who have confirmed ongoing pregnancy at week 10. This is the analysis set for the analysis of Pregnancy Outcome data for the mothers (analysed according to treatment received).

Reporting group title	All infants set - nolasiban
-----------------------	-----------------------------

Reporting group description:

The All Infants (AI) Set consists of all infants born alive. This is the analysis set for the analysis of the Neonatal Health data at birth and at 28 days, and the ASQ-3 data (analysed according to treatment received by the mothers).

Only SAEs were collected for the neonates, therefore added '0' for non-serious AEs.

Reporting group title	All infants set - placebo
-----------------------	---------------------------

Reporting group description:

The All Infants (AI) Set consists of all infants born alive. This is the analysis set for the analysis of the Neonatal Health data at birth and at 28 days, and the ASQ-3 data (analysed according to treatment received by the mothers).

Only SAEs were collected for the neonates, therefore added '0' for non-serious AEs.

In addition to the SAEs provided in the overview, an SAE of congenital pyelocaliectasis was reported in a neonate (placebo) after database lock.

Serious adverse events	Safety analysis set - nolasiban	Safety analysis set - placebo	All women follow-up set - nolasiban
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 399 (2.01%)	8 / 408 (1.96%)	10 / 161 (6.21%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Rhabdomyoma			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Congenital hand malformation			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mandibulofacial dysostosis			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular septal defect			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polydactyly			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aorta hypoplasia			

subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital hydronephrosis			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital ureteric anomaly			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cryptorchism			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Truncus arteriosus persistent			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract malformation			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Selective abortion			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Ectopic pregnancy			
alternative dictionary used: MedDRA 21.1			

subjects affected / exposed	3 / 399 (0.75%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abortion missed			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abortion late			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	2 / 161 (1.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abortion spontaneous			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	2 / 161 (1.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foetal death			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small for dates baby			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine atony			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Reproductive system and breast disorders			
Ovarian hyperstimulation syndrome			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	3 / 399 (0.75%)	5 / 408 (1.23%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Neonatal respiratory distress			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cystitis			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis neonatal			

subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	All women follow-up set - placebo	All infants set - nolasiban	All infants set - placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 160 (1.25%)	6 / 158 (3.80%)	7 / 161 (4.35%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Rhabdomyoma			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Congenital hand malformation			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mandibulofacial dysostosis			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular septal defect			
subjects affected / exposed	0 / 160 (0.00%)	2 / 158 (1.27%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polydactyly			
subjects affected / exposed	0 / 160 (0.00%)	1 / 158 (0.63%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aorta hypoplasia			

subjects affected / exposed	0 / 160 (0.00%)	1 / 158 (0.63%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital hydronephrosis			
subjects affected / exposed	0 / 160 (0.00%)	1 / 158 (0.63%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital ureteric anomaly			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cryptorchism			
subjects affected / exposed	0 / 160 (0.00%)	1 / 158 (0.63%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Truncus arteriosus persistent			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract malformation			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Selective abortion			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Ectopic pregnancy			
alternative dictionary used: MedDRA 21.1			

subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abortion missed			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abortion late			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abortion spontaneous			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foetal death			
subjects affected / exposed	2 / 160 (1.25%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small for dates baby			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine atony			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Reproductive system and breast disorders			
Ovarian hyperstimulation syndrome			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Neonatal respiratory distress			
subjects affected / exposed	0 / 160 (0.00%)	1 / 158 (0.63%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cystitis			
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis neonatal			

subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Safety analysis set - nolasiban	Safety analysis set - placebo	All women follow-up set - nolasiban
Total subjects affected by non-serious adverse events			
subjects affected / exposed	95 / 399 (23.81%)	107 / 408 (26.23%)	12 / 161 (7.45%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Rhabdomyoma			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences (all)	0	0	1
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Hypotension			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Surgical and medical procedures			
Selective abortion			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences (all)	0	0	1
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	27 / 399 (6.77%)	24 / 408 (5.88%)	2 / 161 (1.24%)
occurrences (all)	27	24	2
Biochemical pregnancy			
subjects affected / exposed	9 / 399 (2.26%)	16 / 408 (3.92%)	0 / 161 (0.00%)
occurrences (all)	9	16	0
Abortion missed			
subjects affected / exposed	4 / 399 (1.00%)	6 / 408 (1.47%)	1 / 161 (0.62%)
occurrences (all)	4	6	1
Haemorrhage in pregnancy			

subjects affected / exposed	4 / 399 (1.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	4	1	0
Ectopic pregnancy			
subjects affected / exposed	3 / 399 (0.75%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	3	1	0
Subchorionic haematoma			
subjects affected / exposed	2 / 399 (0.50%)	2 / 408 (0.49%)	0 / 161 (0.00%)
occurrences (all)	2	2	0
Abortion threatened			
subjects affected / exposed	1 / 399 (0.25%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	1	1	0
Imminent abortion			
subjects affected / exposed	1 / 399 (0.25%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	1	1	0
Abortion complete			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Anembryonic gestation			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Gestational diabetes			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	2 / 161 (1.24%)
occurrences (all)	1	0	2
Retained products of conception			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Small for dates baby			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	1 / 161 (0.62%)
occurrences (all)	0	0	1
Abortion late			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	2 / 161 (1.24%)
occurrences (all)	0	0	2
Foetal death			
subjects affected / exposed	0 / 399 (0.00%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Uterine atony			

subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	0 / 408 (0.00%) 0	1 / 161 (0.62%) 1
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 399 (0.50%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	2	0	0
Malaise			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	9 / 399 (2.26%)	12 / 408 (2.94%)	0 / 161 (0.00%)
occurrences (all)	9	12	0
Pelvic pain			
subjects affected / exposed	11 / 399 (2.76%)	7 / 408 (1.72%)	0 / 161 (0.00%)
occurrences (all)	13	7	0
Ovarian hyperstimulation syndrome			
subjects affected / exposed	6 / 399 (1.50%)	9 / 408 (2.21%)	0 / 161 (0.00%)
occurrences (all)	6	12	0
Uterine haematoma			
subjects affected / exposed	1 / 399 (0.25%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	1	1	0
Adnexa uteri pain			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Breast mass			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Breast tenderness			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Genital haemorrhage			

subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Genital swelling			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Uterine haemorrhage			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal burning sensation			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal discomfort			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Vulvovaginal pruritus			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Hyperventilation			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Cardiovascular somatic symptom disorder			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Investigations			
Blood triglycerides increased			
subjects affected / exposed	0 / 399 (0.00%)	2 / 408 (0.49%)	0 / 161 (0.00%)
occurrences (all)	0	2	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0

Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Haematocrit increased subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Heart rate increased subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
International normalised ratio increased subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Prothrombin time prolonged subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Injury, poisoning and procedural complications Procedural pain subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	2 / 408 (0.49%) 2	0 / 161 (0.00%) 0
Congenital, familial and genetic disorders Congenital hand malformation subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	0 / 408 (0.00%) 0	0 / 161 (0.00%) 0
Mandibulofacial dysostosis subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	0 / 408 (0.00%) 0	1 / 161 (0.62%) 1
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	5 / 399 (1.25%) 6	6 / 408 (1.47%) 6	0 / 161 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	3 / 408 (0.74%) 3	0 / 161 (0.00%) 0
Migraine subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	0 / 408 (0.00%) 0	0 / 161 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Blood and lymphatic system disorders			
Hypercoagulation subjects affected / exposed occurrences (all)	2 / 399 (0.50%) 2	2 / 408 (0.49%) 2	0 / 161 (0.00%) 0
Anaemia subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Disseminated intravascular coagulation subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	0 / 408 (0.00%) 0	1 / 161 (0.62%) 1
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	8 / 399 (2.01%) 9	5 / 408 (1.23%) 5	0 / 161 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	2 / 399 (0.50%) 2	3 / 408 (0.74%) 3	0 / 161 (0.00%) 0

Vomiting			
subjects affected / exposed	2 / 399 (0.50%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	2	1	0
Abdominal distension			
subjects affected / exposed	0 / 399 (0.00%)	2 / 408 (0.49%)	0 / 161 (0.00%)
occurrences (all)	0	2	0
Abdominal pain lower			
subjects affected / exposed	2 / 399 (0.50%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	2	0	0
Constipation			
subjects affected / exposed	1 / 399 (0.25%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	1	1	0
Abdominal pain			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Ascites			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Dermatitis allergic			
subjects affected / exposed	1 / 399 (0.25%)	0 / 408 (0.00%)	0 / 161 (0.00%)
occurrences (all)	1	0	0
Rash pruritic			
subjects affected / exposed	0 / 399 (0.00%)	1 / 408 (0.25%)	0 / 161 (0.00%)
occurrences (all)	0	1	0
Endocrine disorders			

Hypothyroidism subjects affected / exposed occurrences (all)	2 / 399 (0.50%) 2	3 / 408 (0.74%) 3	0 / 161 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	2 / 399 (0.50%) 2	0 / 408 (0.00%) 0	0 / 161 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 2	0 / 161 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	0 / 408 (0.00%) 0	0 / 161 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	0 / 408 (0.00%) 0	0 / 161 (0.00%) 0
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	2 / 399 (0.50%) 2	3 / 408 (0.74%) 3	0 / 161 (0.00%) 0
Cystitis subjects affected / exposed occurrences (all)	2 / 399 (0.50%) 2	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Herpes virus infection subjects affected / exposed occurrences (all)	2 / 399 (0.50%) 2	0 / 408 (0.00%) 0	0 / 161 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Bacteriuria subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	0 / 408 (0.00%) 0	0 / 161 (0.00%) 0
Sinusitis			

subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 399 (0.25%) 1	0 / 408 (0.00%) 0	0 / 161 (0.00%) 0
Varicella zoster virus infection subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Metabolism and nutrition disorders			
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 399 (0.00%) 0	1 / 408 (0.25%) 1	0 / 161 (0.00%) 0

Non-serious adverse events	All women follow-up set - placebo	All infants set - nolasiban	All infants set - placebo
Total subjects affected by non-serious adverse events subjects affected / exposed	8 / 160 (5.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rhabdomyoma subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Vascular disorders			
Hot flush subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Hypotension subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Surgical and medical procedures			
Selective abortion			

subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Biochemical pregnancy subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Abortion missed subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Haemorrhage in pregnancy subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Ectopic pregnancy subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Subchorionic haematoma subjects affected / exposed occurrences (all)	1 / 160 (0.63%) 1	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Abortion threatened subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Imminent abortion subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Abortion complete subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Anembryonic gestation subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Gestational diabetes			

subjects affected / exposed	2 / 160 (1.25%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	2	0	0
Retained products of conception			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Small for dates baby			
subjects affected / exposed	2 / 160 (1.25%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	2	0	0
Abortion late			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Foetal death			
subjects affected / exposed	2 / 160 (1.25%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	2	0	0
Uterine atony			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Ovarian hyperstimulation syndrome			

subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Uterine haematoma			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Adnexa uteri pain			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Breast mass			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Breast tenderness			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Genital haemorrhage			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Genital swelling			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Uterine haemorrhage			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal burning sensation			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal discomfort			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Hyperventilation			

subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Psychiatric disorders Cardiovascular somatic symptom disorder subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Investigations Blood triglycerides increased subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 2	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Haematocrit increased subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Heart rate increased subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
International normalised ratio increased subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Prothrombin time prolonged subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Injury, poisoning and procedural complications Procedural pain			

subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Congenital, familial and genetic disorders			
Congenital hand malformation subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Mandibulofacial dysostosis subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Cardiac disorders			
Palpitations subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Migraine subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Blood and lymphatic system disorders			
Hypercoagulation subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Anaemia subjects affected / exposed occurrences (all)	1 / 160 (0.63%) 1	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0

Leukocytosis			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Ascites			

subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Dyspepsia subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Flatulence subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Skin and subcutaneous tissue disorders Dermatitis allergic subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Rash pruritic subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 160 (0.00%) 0	0 / 158 (0.00%) 0	0 / 161 (0.00%) 0
Infections and infestations			

Nasopharyngitis			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Herpes virus infection			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Bacteriuria			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Varicella zoster virus infection			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperlipidaemia			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	0 / 160 (0.00%)	0 / 158 (0.00%)	0 / 161 (0.00%)
occurrences (all)	0	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 November 2018	<ul style="list-style-type: none">- Specification that 3 PK samples were to be collected at 3.5 h, 5 h, and ≥ 7 h (up to a maximum of 72 h) following nolasiban/placebo administration.- Specification that nolasiban concentration was to be measured in plasma (instead of serum).- Clarification that the PK analysis set would include only those subjects who received active study medication (i.e., nolasiban).- Clarification that population PK analyses would be described and reported separately.- Specification that blood samples for measurement of P4 and E2 were to be collected on the day before/of hCG injection.- Addition of a schematic diagram to clarify the assessments and procedures to be performed at the baseline visit.- Specification that analysis of rates of live birth and pregnancy loss would be performed using a gestational age limit of 22 weeks in addition to the analyses using 20-week and 24-week limits.- Addition of ASQ-3 questionnaire completion at 12 months.- Specification that miscarriage or foetal death in utero after 10 weeks of pregnancy was to be considered an SAE, and that spontaneous abortions before 10 weeks were to be reported as AEs and as "pregnancy and obstetrical outcomes of interest."- Introduction of the category of "pregnancy and obstetrical outcomes of interest," with resulting change to the eCRF AE forms.- Description of the destruction of (un)used IMP.
07 August 2019	<ul style="list-style-type: none">- Specification that PK would also be analysed for nolasiban metabolites and clarification that PK results were to be reported separate from the main CSR.- Removal of the analysis of live birth at 20 weeks of gestation.- Clarification of the definition of pregnancy loss.- Addition of the requirement that any congenital anomalies be confirmed by a dysmorphologist.- Addition of the collection of information from an infant physical examination at 12 months.- Introduction of separate study objectives, endpoints, and analyses for the US health authorities
02 December 2019	<ul style="list-style-type: none">- Removal of the collection of the ASQ-3 and infant physical examination at 12-months.- Removal of US objectives, endpoints and analysis which were introduced in amendment 2 (protocol version 3.0).- Clarification that the verification of congenital anomalies by a dysmorphologist is managed by the Sponsor.- Correction to categories of pre-term births.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Of 807 subjects treated, 321 had confirmed pregnancies at Week 10. Follow-up (FU) data were provided for 329 fetuses. Pregnancies resulted in live birth for 313 subjects, assuming +ve outcome in case of loss to FU. Neonatal FU data on 319 infants.

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/33534895>